Booster Effect of mRNA Vaccine on Antibody Response for SARS-CoV-2 After Complete Vaccination With Sinos

• Conditions: Vaccine Reaction

• Registration Number: NCT05213455
• Lead Sponsor: Lahore General Hospital

Brief Summary

In most parts of the world, mRNA vaccines were used to provide protection to population against COVID 19. However, in some countries, including Pakistan, traditional viral vaccines named as Sinovac and Sinopharm were used for mass level immunization. Though these vaccines were approved by WHO, their efficacy had been questioned.

Now after recommendation of booster doses, we aim to see the effect of mRNA vaccine as a booster dose after Sinovac and Sinopharm in terms of antibody response. (IgG RBD SARS CoV2)

Detailed Description

In most parts of the world, mRNA vaccines were used to provide protection to population against COVID 19. However, in some countries, including Pakistan, traditional viral vaccines named as Sinovac and Sinopharm were used for mass level immunization. Though these vaccines were approved by WHO, their efficacy had been questioned.

Now after recommendation of booster doses, we aim to see the effect of mRNA vaccine (BNT162b2, pfizer) as a booster dose after Sinovac and Sinopharm in terms of antibody response. (IgG RBD SARS CoV2).

The antobody IgG RBD levels will be checked before the booster dose and then after 3 weeks of the booster.

Study Timeline

• Study Start: 2022-01-01
• Study First Submitted: 2022-01-16
• Study First Submitted QC: 2022-01-16
• Study First Posted: 2022-01-28
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-12
• Primary Completion: 2022-02-28
• Last Update Posted: 2022-03-02
• Study Completion: 2022-03-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• people who have received two doses of sinopharm or sinovac and six months have passed after the second dose

Exclusion Criteria

• people getting one shot of sinopharm or sinovac or got vaccine other than sinopharm and sinovac.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IgG RBD levels	after 3 weeks of booster vaccine dose	to see the effect of booster vaccine after 3 weeks in terms of IgG RBD

Trial Locations

Locations (1)

Lahore General Hospital; 🇵🇰 Lahore, Punjab, Pakistan